DE69927805D1 - Neue fettanaloge zur behandlung von sekundärer restenose - Google Patents

Neue fettanaloge zur behandlung von sekundärer restenose

Info

Publication number
DE69927805D1
DE69927805D1 DE69927805T DE69927805T DE69927805D1 DE 69927805 D1 DE69927805 D1 DE 69927805D1 DE 69927805 T DE69927805 T DE 69927805T DE 69927805 T DE69927805 T DE 69927805T DE 69927805 D1 DE69927805 D1 DE 69927805D1
Authority
DE
Germany
Prior art keywords
sub
treatment
new fat
fat analogue
restenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927805T
Other languages
English (en)
Other versions
DE69927805T2 (de
Inventor
Rolf Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thia Medica AS
Original Assignee
Thia Medica AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica AS filed Critical Thia Medica AS
Application granted granted Critical
Publication of DE69927805D1 publication Critical patent/DE69927805D1/de
Publication of DE69927805T2 publication Critical patent/DE69927805T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69927805T 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose Expired - Fee Related DE69927805T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
WOPCT/NO98/00143 1998-05-08
PCT/NO1999/000149 WO1999058123A2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis

Publications (2)

Publication Number Publication Date
DE69927805D1 true DE69927805D1 (de) 2006-03-02
DE69927805T2 DE69927805T2 (de) 2006-07-06

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks

Country Status (18)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1075258B1 (de)
JP (3) JP2002514595A (de)
KR (3) KR100701502B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE247464T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331395C (de)
DE (5) DE69909775T2 (de)
DK (3) DK1075259T3 (de)
ES (3) ES2204142T3 (de)
HK (3) HK1034911A1 (de)
NO (3) NO20005461L (de)
NZ (3) NZ508045A (de)
PT (2) PT1075259E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
SI1547614T1 (sl) * 2002-05-28 2011-04-29 Ajinomoto Kk Medicinski sestavek za inhibiranje izraĺ˝anja atp-citrat-liaze in uporaba le-tega
RU2331649C2 (ru) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Серосодержащие фосфолипидные производные, содержащая их фармацевтическая композиция, их применение для лечения заболеваний и способ их получения
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
KR20050033662A (ko) 2002-09-06 2005-04-12 얀센 파마슈티카 엔.브이. 헤테로사이클릭 화합물
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
NZ539106A (en) * 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
ES2660700T3 (es) * 2004-07-19 2018-03-23 Bergen Teknologioverføring As Composición que comprende aceites vegetales y/o de pescado y entidades de ácidos grasos no oxidables
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
WO2006117664A1 (en) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
BRPI0718420A2 (pt) 2006-10-20 2013-11-12 Cpd Llc Método de restabelecimento do efeito da incretina
CA2667150A1 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
KR20100100818A (ko) * 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 새로운 ｄｈａ 유도체 및 약물로서 그들의 사용
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
RU2502727C2 (ru) * 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-триметиламмониобутираты в качестве ингибиторов срт2
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
PT2427415T (pt) 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103237546B (zh) 2010-07-28 2016-06-08 生命科技公司 抗病毒的含有叠氮化物的化合物
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
KR102265409B1 (ko) 2010-11-05 2021-06-16 바스프 에이에스 지질 화합물을 이용한 치료방법
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
JP7312184B2 (ja) * 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP7404382B2 (ja) * 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
ATE306916T1 (de) 2005-11-15
US6365628B1 (en) 2002-04-02
AU4936699A (en) 1999-11-29
WO1999058123A3 (en) 2000-03-09
HK1034911A1 (en) 2001-11-09
CN1244323C (zh) 2006-03-08
KR100701502B1 (ko) 2007-04-02
CA2331408C (en) 2008-10-21
NO20005463D0 (no) 2000-10-30
AU762792B2 (en) 2003-07-03
NO20005463L (no) 2001-01-08
CA2331393A1 (en) 1999-11-18
RU2223095C2 (ru) 2004-02-10
DE69932864D1 (de) 2006-09-28
CA2331393C (en) 2009-08-11
ATE245416T1 (de) 2003-08-15
JP5057003B2 (ja) 2012-10-24
JP4465672B2 (ja) 2010-05-19
AU5451799A (en) 1999-11-29
WO1999058121A1 (en) 1999-11-18
KR20010043316A (ko) 2001-05-25
DK1075260T3 (da) 2006-02-06
CN1302204A (zh) 2001-07-04
ES2204142T3 (es) 2004-04-16
EP1075258A1 (de) 2001-02-14
KR20010043314A (ko) 2001-05-25
CA2331395A1 (en) 1999-11-18
WO1999058123A2 (en) 1999-11-18
EP1075260A2 (de) 2001-02-14
AU7240398A (en) 1999-11-29
JP2002514595A (ja) 2002-05-21
DE69909775T2 (de) 2004-06-03
AU762790B2 (en) 2003-07-03
EP1075259B1 (de) 2003-07-23
DK1075259T3 (da) 2003-11-03
NO20005461L (no) 2001-01-08
PT1075259E (pt) 2003-12-31
WO1999058120A1 (en) 1999-11-18
DE69910559T2 (de) 2004-06-17
US7026356B2 (en) 2006-04-11
NO20005461D0 (no) 2000-10-30
NZ508045A (en) 2003-08-29
EP1075258B1 (de) 2003-08-20
KR20010043315A (ko) 2001-05-25
AU761355B2 (en) 2003-06-05
BR9910296A (pt) 2002-01-15
KR100701503B1 (ko) 2007-04-02
AU4936799A (en) 1999-11-29
EP1285652A1 (de) 2003-02-26
US20020198259A1 (en) 2002-12-26
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
ATE247464T1 (de) 2003-09-15
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
DE69932645D1 (de) 2006-09-14
EP1075259A1 (de) 2001-02-14
HK1034909A1 (en) 2001-11-09
KR100822077B1 (ko) 2008-04-14
DE69910559D1 (de) 2003-09-25
ATE336239T1 (de) 2006-09-15
CA2331395C (en) 2008-10-14
NZ508046A (en) 2003-08-29
RU2221558C2 (ru) 2004-01-20
WO1999058122A1 (en) 1999-11-18
DK1075258T3 (da) 2003-12-01
DE69927805T2 (de) 2006-07-06
PT1075258E (pt) 2004-01-30
NO333143B1 (no) 2013-03-18
CN1223343C (zh) 2005-10-19
CN1245157C (zh) 2006-03-15
RU2219920C2 (ru) 2003-12-27
CA2331408A1 (en) 1999-11-18
US6441036B1 (en) 2002-08-27
CN1300212A (zh) 2001-06-20
ATE334666T1 (de) 2006-08-15
NO20005462D0 (no) 2000-10-30
EP1285652B1 (de) 2006-08-16
JP2002514596A (ja) 2002-05-21
NO20005462L (no) 2001-01-08
JP2002514594A (ja) 2002-05-21
NZ508047A (en) 2003-05-30
DE69909775D1 (de) 2003-08-28
EP1284139B1 (de) 2006-08-02
US6417232B1 (en) 2002-07-09
EP1284139A1 (de) 2003-02-19
ES2251218T3 (es) 2006-04-16
CN1300211A (zh) 2001-06-20

Similar Documents

Publication Publication Date Title
DE69927805D1 (de) Neue fettanaloge zur behandlung von sekundärer restenose
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
NZ335981A (en) Ketobenzamides as calpain inhibitors
ATE263157T1 (de) Nematizide trifluorbutene
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
NO984950D0 (no) Forbindelser med veksthormonfrigj°rende egenskaper
ATE283256T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ATE157660T1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
TR199700416A2 (xx) Fluorinlenmi� vitamin D3 analoglar�.
DE60204014D1 (de) Chlormethylierung von thiophene
BR9808210A (pt) Befeniloxazolinas dissubstituìdas
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee